Paper28075166
The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
Chen X and 9 others. Future Oncol, 2017. Cited by 100 papers, by iCite.
Cite this record
ConductScience Library. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Papers, record 28075166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28075166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Biomarkers, Tumor | Major topic |
| Breast Neoplasms | Major topic |
| Ki-67 Antigen | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | |
| Female | |
| Humans | |
| Neoadjuvant Therapy | |
| Odds Ratio | |
| Prognosis | |
| Publication Bias | |
| Treatment Outcome |
Source PubMed
Cited by80
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42801232 | Investigation of the Residual Tumor Burden and Prognosis of Breast Cancer. | Breast Cancer (Dove Med Press) | 2026 | https://conductscience.org/library/papers/42801232 | PubMed |
| 42741650 | Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer. | Oncol Lett | 2026 | https://conductscience.org/library/papers/42741650 | PubMed |
| 42279314 | Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42279314 | PubMed |
| 42157210 | A nomogram integrating p53 and Ki-67 expression for predicting recurrence risk in postoperative early gastric cancer. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/42157210 | PubMed |
| 41620483 | Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy. | Sci Rep | 2026 | https://conductscience.org/library/papers/41620483 | PubMed |
| 41411609 | Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer. | JCO Precis Oncol | 2025 | https://conductscience.org/library/papers/41411609 | PubMed |
| 41368527 | Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer. | Front Surg | 2025 | https://conductscience.org/library/papers/41368527 | PubMed |
| 41224966 | Temporality of change in Ki67 labelling following neoadjuvant systemic chemotherapy of breast cancer-the common drop often subsides with time. | Virchows Arch | 2026 | https://conductscience.org/library/papers/41224966 | PubMed |
| 41182476 | Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/41182476 | PubMed |
| 40824193 | Predictive value of shear wave elastography and molecular subtypes for postoperative efficacy in patients with early breast cancer. | Ann Med | 2025 | https://conductscience.org/library/papers/40824193 | PubMed |
| 40718834 | The impact of circWWC3 on neoadjuvant therapy for triple-negative breast cancer and the construction of a nomogram for predicting pathological complete response after neoadjuvant therapy. | Front Oncol | 2025 | https://conductscience.org/library/papers/40718834 | PubMed |
| 40667551 | Machine learning-based prediction of disease-free survival in breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy: a retrospective multicenter cohort study. | Am J Cancer Res | 2025 | https://conductscience.org/library/papers/40667551 | PubMed |
| 40583394 | Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection. | Future Oncol | 2025 | https://conductscience.org/library/papers/40583394 | PubMed |
| 40437449 | Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world. | BMC Cancer | 2025 | https://conductscience.org/library/papers/40437449 | PubMed |
| 40201702 | Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review. | Health Sci Rep | 2025 | https://conductscience.org/library/papers/40201702 | PubMed |
| 40176396 | Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data. | Thorac Cancer | 2025 | https://conductscience.org/library/papers/40176396 | PubMed |
| 39799529 | The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study. | Breast Cancer Res Treat | 2025 | https://conductscience.org/library/papers/39799529 | PubMed |
| 39773380 | The value of multiparametric MRI radiomics and machine learning in predicting preoperative Ki-67 expression level in breast cancer. | BMC Med Imaging | 2025 | https://conductscience.org/library/papers/39773380 | PubMed |
| 39736579 | Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA. | BMC Womens Health | 2024 | https://conductscience.org/library/papers/39736579 | PubMed |
| 39734711 | Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression. | Ther Adv Med Oncol | 2024 | https://conductscience.org/library/papers/39734711 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| MKI67 | 4288 | PubTator's text mining | https://conductscience.org/library/genes/4288 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28075166
GET https://conductscience.org/api/papers/v1/28075166/cited_by?page=2